Revance Therapeutics (RVNC)

Revance Therapeutics Stock Analysis & Ratings

RVNC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$11.65 - $33.83
Previous Close$15.59
Average Volume (3M)688.21K
Market Cap$1.13B
P/E Ratio-3.7
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score9
EPS (TTM)-4.17



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $11.65 and its highest was $33.83 in the past 12 months.
    What is Revance Therapeutics’s market cap?
    Revance Therapeutics’s market cap is $1.13B.
      What is Revance Therapeutics’s price target?
      The average price target for Revance Therapeutics is $23.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $26.00 ,the lowest forecast is $20.00. The average price target represents 51.83% Increase from the current price of $15.59.
        What do analysts say about Revance Therapeutics?
        Revance Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Revance Therapeutics’s upcoming earnings report date?
          Revance Therapeutics’s upcoming earnings report date is Aug 04, 2022 which is in 78 days.
            How were Revance Therapeutics’s earnings last quarter?
            Revance Therapeutics released its earnings results on May 10, 2022. The company reported -$0.651 earnings per share for the quarter, beating the consensus estimate of -$0.797 by $0.146.
              Is Revance Therapeutics overvalued?
              According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
                Does Revance Therapeutics pay dividends?
                Revance Therapeutics does not currently pay dividends.
                What is Revance Therapeutics’s EPS estimate?
                Revance Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Revance Therapeutics have?
                Revance Therapeutics has 72,770,000 shares outstanding.
                  What happened to Revance Therapeutics’s price movement after its last earnings report?
                  Revance Therapeutics reported an EPS of -$0.651 in its last earnings report, beating expectations of -$0.797. Following the earnings report the stock price went down -11.036%.
                    Which hedge fund is a major shareholder of Revance Therapeutics?
                    Among the largest hedge funds holding Revance Therapeutics’s share is HealthCor Management, L.P.. It holds Revance Therapeutics’s shares valued at 28M.


                      Revance Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(51.83% Upside)
                      Strong Buy
                      The Revance Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Revance Therapeutics

                      Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

                      Similar Stocks
                      Price & Change
                      Procter & Gamble
                      Aclaris Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis